CRISPR Therapeutics AG (CRSP) Non-Current Debt (2026)
CRISPR Therapeutics AG's (CRSP) quarterly Non-Current Debt came in at $586.2 million in Q2 2026, little changed quarter-over-quarter from $585.5 million in Q1 2026.
Powered by 
Analysis
CRISPR Therapeutics AG (CRSP) Non-Current Debt (2026) Analysis & Trends
CRISPR Therapeutics AG has disclosed Non-Current Debt across 1 years of filings, most recently posting $586.2 million for Q2 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.27 Bn | 9.43 Bn | 112.79 Mn | - |
| 2 | CRISPR Therapeutics AG | 5.17 Bn | 5.17 Bn | - | 586.20 Mn |
| 3 | Iovance Biotherapeutics | 3.79 Bn | 3.49 Bn | 55.72 Mn | - |
| 4 | Legend Biotech | 3.68 Bn | 2.71 Bn | 251.50 Mn | - |
| 5 | uniQure | 3.05 Bn | 3.05 Bn | 5.49 Mn | 50.15 Mn |
| 6 | Beam Therapeutics | 2.65 Bn | 2.65 Bn | - | 100.26 Mn |
| 7 | Precigen | 2.44 Bn | 2.44 Bn | 52.17 Mn | 93.88 Mn |
| 8 | Sarepta Therapeutics | 2.33 Bn | 1.53 Bn | 251.87 Mn | 847.62 Mn |
| 9 | Vericel | 1.99 Bn | 1.83 Bn | 56.40 Mn | - |
| 10 | Taysha Gene Therapies | 1.97 Bn | 1.97 Bn | - | 49.26 Mn |